Cysteinyl Leukotriene Receptor 1 (CYSLTR1) ELISA Kits

Human Cysteinyl Leukotriene Receptor 1 (CYSLTR1) interaction partners

1. Drugs antagonizing the CysLT1 receptor, termed lukasts and typified by montelukast, are established therapeutics for clinical management of asthma.. Here we describe recent data indicating that montelukast may be used for prevention and treatment of AAA, thus representing a promising pharmacological tool for a deadly vascular disease with significant socio-economic impact.

2. findings strongly implicate that cysLTR1 has the capacity to regulate cellular senescence in chondrocytes. It is suggested that montelukast may be a potential therapeutic agent for chondro-protective therapy.

3. The expression of CysLTR1 and CysLTR2 is higher in the lymphocytes of hyperplasic tonsils in nonallergic children

4. SE sensitization may be a risk factor for TH2 inflammation in nonatopic asthma and late-onset asthma and for pulmonary function decline in nonatopic asthma. In women with asthma, a CysLTR1 promoter polymorphism may be associated with SEB sensitization.

5. In addition, TGF-beta1-induced expression of MMP-1 and MMP-3, generation of fibronectin and type I collagen production, focal adhesion kinase (FAK) and paxillin phosphorylation in HTFs were also ameliorated by montelukast in a dose dependent manner. These results suggested that montelukast might provide therapeutic possibilities for inhibition of scar formation after such surgery.

6. CysLTRs -1 and -2 seem to be involved in lymphocyte maturation that occurs in tonsils, without influence of allergies.

7. Data show that cysteinyl leukotriene receptor antagonists (LTRAs) users had a significantly lower cancer incidence rate than LTRA non-users did.

8. in allergen-sensitized individuals, exposure to allergen can enhance T cell expression of CysLT1. This, in turn, would induce enhanced CD4+ T cell responsiveness to cysLTs, T cell activation, and Th2 polarization.

9. CysLTR-1 and CysLTR-2 are highly expressed in the adenoid tissues from children with AH, suggesting that leukotrienes are involved in the pathogenesis of AH.

10. The 5-LOX/LTC4 /CysLT1 signaling pathway regulates EGF-induced cell migration by increasing Tiam1 expression.

11. Cysteinyl leukotrienes signaling downstream of CysLT1R in mast cells is differentially regulated by two distinct PKCalpha and PKC epsilon.

12. CysLT(1) receptors in endothelial cells translocate to the nucleus in a ligand-independent manner after ischemic insult in vitro, and it is involved in the ischemic injury.

13. A significant relationship was found between the expression of CysLT1 receptor and GR-beta in nasal polyps (R = .525, P = .04), whereas there was no significant relationship between the expression of CysLT1 receptor and GR-alpha in nasal polyps.

14. Genetic variant may play a role in NSAID induced acute urticaria.

15. A role of nuclear CysLT(1) receptor signaling in vascular smooth muscle cells inducing gene expression patterns associated with atherosclerosis.

16. Bronchial mucosal CysLT1 receptor-positive inflammatory cells are present in the bronchial mucosa in COPD in greatest number in those experiencing a severe exacerbation.

17. increased expression in tonsillar tissues of Chinese children with sleep-disordered breathing

18. Data suggest that CysLT1 induces chemokine-like effects, supports accumulation and survival of chronic lymphocytic leukemia (CLL) cells in the bone marrow and thus represents a potential treatment target.

19. cysteinyl-leukotriene receptors are differently expressed in fibroblast from peripheral versus central airways in asthmatics and healthy controls.

20. upon ligand activation, CysLT(1)R is tyrosine-phosphorylated and released from heterodimers with CysLT(2)R and, subsequently, internalizes from the plasma membrane to the nuclear membrane in a clathrin-, arrestin-3-, and Rab-5-dependent manner

Mouse (Murine) Cysteinyl Leukotriene Receptor 1 (CYSLTR1) interaction partners

1. Cysteinyl leukotriene receptor 1 (cysLT1R) regulates osteoclast differentiation and bone resorption.

2. Montelukast also served a protective role in a murine ovariectomy (OVX) and unloadinginduced bone loss model. Altogether, these results confirmed that the CysLTR1 antagonist exerted an inhibitory effect on OC formation in vitro and in vivo. It may be useful for the treatment of bone diseases associated with excessive bone resorption.

3. The study presents a genetic approach in a colitis-associated colon cancer model further supporting an important role for CysLT1R signaling in colon tumorigenesis, driving immune mediators to promote immune cell infiltration in tumors.

4. Mechanistically, the effect of montelukast on osteoblastic differentiation acted by activating the extracellular regulated protein kinases (ERK) pathway. The obtained results suggested that montelukast promotes proliferation and differentiation in osteoblasts exposed to overload mechanics.

5. this study shows that CysLT1R-deficient mice that were exposed to chlorine demonstrated airway hyperresponsiveness to inhaled methacholine significantly greater than in wild-type BALB/c mice

6. The important role that CysLTR1 plays in colorectal cancer and intestinal polyps development.

7. Leukotriene D4 and prostaglandin E2 signals synergize and potentiate vascular inflammation in a mast cell-dependent manner through cysteinyl leukotriene receptor 1 and E-prostanoid receptor 3

8. Involvement of CysLT1R in a model of asthma.

9. Suggest that myogenic tone is determined by AT1 and CysLT1 receptors acting together as mechanosensors via Gq/11-protein activation.

10. It plays a critical role in Ab1e42-induced neurotoxicity.

11. The CysLT(1) and CysLT(2) receptors were primarily localized in neurons, microglia and neutrophils

12. CysLT1R mediates LTD4-induced activation of microglial cells.

13. In an animal model of cognition impairment, CysLT1 receptor signaling is identified as proinflammatory and proamyloidogenic.

14. a single mutation of Thr151Gly in the 2nd inner loop of sysLT1 had a slight inhibitory effect on the desensitization.

15. present novel data that CysLT1R is expressed on ILC2s and LTD potently induces CysLT1R-dependent ILC2 production of IL-4, IL-5, and IL-13

16. CysLT1R, CysLT2R and GPR17 might be involved in the MPTP-induced Parkinson disease damage in mice.

17. 5-Lipoxygenase mediates RANKL-induced osteoclast formation via the cysteinyl leukotriene receptor 1, and it can serve as a novel therapeutic target for bone-resorption diseases.

18. leukotriene D(4) recepter may be involved in the development of seizures in mice.

19. Rotenone induced an increased expression of CysLT(1) receptor in BV2 microglial cells.

20. Cysltr1-deficient C57BL/6 mice are protected from pulmonary inflammation both in active house dust mite sensitization and challenge, revealing a broad and dose-related role for CysLT1R in antigen presentation and downstream responses.